
On June 22, 2017, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicine’s Agency (“EMA”)...
By C. Nichole Gifford Comments are off
On June 22, 2017, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicine’s Agency (“EMA”)...
Tagged with: AbbVie, adalimumab, Biogen, EMA, FDA, Humira®, Imraldi®, News, Regulatory, Samsung Bioepsis
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Over the last two weeks, Pfizer, Inc. (“Pfizer”) has filed petitions for inter partes review (“IPR”) of three additional patents...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
FDA approved Samsung Bioepis’s Renflexis® (SB2, infliximab-abda) on Friday, April 21, 2017. Renflexis® is the fifth biosimilar...
Tagged with: Biogen, Celltrion, FDA, Inflectra®, Infliximab, Janssen, News, Regulatory, Remicade®, Renflexis®, Samsung Bioepsis
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Pfizer, Inc. (“Pfizer”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on March 24, 2017, for inter partes...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Celltrion, Inc. (“Celltrion”) filed three new petitions with the Patent Trial and Appeal Board (“PTAB”) on March 15, 2017 for inter...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Samsung Bioepsis UK Limited (“Samsung”), Biogen Idec Limited (“Biogen”), and Fujifilm Kyowa Kirin Biologic Company Limited...
Tagged with: AbbVie, adalimumab, Biogen, Fujifilm Biologics, Humira®, Invalidity, Legal, Litigation, News, Samsung Bioepsis
ShareEmail, Linked In, Twitter, Facebook, Google Plus